3rd Genetic Vaccine Development for Infectious Diseases Summit

The 3rd Genetic Vaccine Development for Infectious Disease Summit 2023 returns to Boston to unite world leaders in vaccine development. This year leading industry minds are gathering to overcome critical bottlenecks in genetic vaccine R&D and review pioneering platforms to expand the horizon toward treatments of untreated pathogens to provide better treatments to prevent and cure diseases for patients in need.

Curated for biopharma leaders looking to integrate novel vaccine development approaches into their R&D efforts through pre-clinical studies to clinical translation. This forum is shining a spotlight on applications toward future successes in DNA and viral vector vaccines.

Join 80+ leading vaccine developers from infectious diseases and virology for this one-of-a-kind event. Together we revolutionize the next era of vaccinology to prevent infectious diseases worldwide.

URLs:
Brochure: https://go.evvnt.com/1453838-0?pid=176
Website: https://go.evvnt.com/1453838-1?pid=176
Tickets: https://go.evvnt.com/1453838-2?pid=176

Prices:
Drug Developer - Conference + Workshop Day: USD 4946.00,
Drug Developer - Conference Only: USD 2999.00,
Solution Provider - Conference + Workshop Day: USD 5846.00,
Solution Provider - Conference Only: USD 3599.00,
Academic - Conference + Workshop Day: USD 4246.00,
Academic - Conference Only: USD 2599.00

Speakers: Ami Patel, Caspar Wistar Fellow, The Wistar Institute, Christopher Cooper, Director - Viral Vaccines, Vaccine Design and Development Laboratory, International AIDS Vaccine Initiative (IAVI), Chunlin Xin, VP, CanSino Biologics Inc., Darina Spasova, Director - Pharmacology, Replicate Bioscience, Demin Zhu, Chief Executive Officer, Cureport, Inc, Gunnstein Norheim, Director Infectious Diseases, Nykode Therapeutics, Heinrich Haas, Vice President, RNA Formulation and Drug Delivery, BioNTech AG, Jakob Cramer, Head Of Clinical Development, CEPI, Jesse Erasmus, Director - Virology, HDT Bio, Joshua DiNapoli, Global Project Head, Sanofi, Judith Alamares-Sapuay, Biotherapeutics Manager, Sanofi Pasteur, Kay Hunsberger, Executive Director, Merck and Co, Mohamed ElSayed, Executive Vice President and Chief Technology Officer, RVAC Medicines, Nerea Zabaleta, Instructor, Beth Israel Deaconess Medical Center, Robert Van Den Berg, Independent Expert, Vaccine Technologies, Shan Lu, Professor, University of Massachusetts Medical School, Simon van Haren, Principal Investigator, Precision Vaccines Program, Boston Children's Hospital, Children's Hospital Boston, Stephen Shrewsbury, Chief Medical Officer, Impel Pharmaceuticals Inc., Sunetra Gupta, Professor, University of Oxford, Trevor Smith, Vice President, Inovio Pharmaceuticals

Time: 8:00 am to 5:30 pm